Eris Lifesciences Gains Major Entry into Brazilian Market

Eris Lifesciences announced that one of its manufacturing units in Ahmedabad has obtained approval from Brazil's regulatory agency ANVISA. This approval, following a May 2025 inspection, allows the company to access Brazil's pharmaceutical market, the largest in South America. Company's shares showed a slight increase.

Devdiscourse News Desk | New Delhi | Updated: 25-08-2025 14:06 IST | Created: 25-08-2025 14:06 IST

Eris Lifesciences Gains Major Entry into Brazilian Market — This image is AI-generated and does not depict any real-life event or location. It is a fictional representation created for illustrative purposes only.

Country:
India

In a significant development for Eris Lifesciences, the company has secured approval from Brazil's national health regulatory body, ANVISA, for one of its manufacturing sites in Ahmedabad.

This approval comes on the heels of a successful inspection carried out by ANVISA in May 2025, paving the way for the drug manufacturer to step into Brazil, South America's largest pharmaceutical market.

Following the announcement, Eris Lifesciences witnessed a modest rise in its stock prices, with shares trading at a slight increase to Rs 1,772.50 on the BSE.

(With inputs from agencies.)